Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Parkinson's: Page 2
Experts seek consensus on genes to include in Parkinson's tests
By
Leah Sherwood
"Our findings highlight the urgent need for expert opinion on which genes and variants commercial laboratory services should consider for general PD panels and other PD-related panels," wrote the research group, led by Lola Cook of Indiana University.
October 27, 2021
BrainChip, NaNose laud progress in breath sample COVID-19 test
By
LabPulse.com staff writers
The test incorporates NaNose Medical's sensor array to collect data and BrainChip's Akida artificial intelligence chip to perform the diagnosis, according to the two firms. NaNose's sensory array is based on technology developed at Technion Israel Institute of Technology in Haifa, and has similar sensitivity to minute quantities of volatile organic compounds (VOCs) as a dog's nose.
February 24, 2021
Parkinson's Foundation demonstrates role of genetic testing in pilot study
By
LabPulse.com staff writers
The study offered free genetic testing of clinically relevant Parkinson's-related genes and free genetic counseling to help participants better understand their results. The preliminary findings demonstrated the feasibility of conducting comprehensive genetic testing and genetic counseling for the disease and identified rare genetic mutation carriers linked to the disease.
July 7, 2020
Alpha-synuclein saliva biomarker for Parkinson's not ready for prime time
By
Emily Hayes
Researchers at the University of Athens evaluated the use of salivary α-Syn as a diagnostic marker in eight trials including a total of 1,240 patients identified through a systematic review of 476 studies. They found different results depending on the way α-Syn was measured -- total α-Syn versus oligomeric salivary α-Syn.
August 18, 2019
Parkinson's Foundation kicks off genetic testing program
By
LabPulse.com staff writers
The program -- dubbed PD GENEration -- will kick off at Columbia University Irving Medical Center, but other pilot sites will come on board later. Results will be stored and used for research purposes. The plan is to initially offer the testing program to 600 participants, and later roll it out to U.S. 50 centers by 2020; the foundation's long-term aim is to include 15,000 Parkinson's patients.
July 15, 2019
Cerebrospinal fluid test helps pinpoint dementia disorders
By
Emily Hayes
The meta-analysis of studies involving about 10,000 people with neurological disorders showed that neurofilament light protein as measured with a commercially available immunoassay was elevated for people with neurological and psychiatric conditions. Results were broadly similar; however, frontotemporal dementia and HIV-related cognitive decline were differentiated from other dementias, and Parkinson's disease was differentiated from atypical parkinsonian conditions.
June 17, 2019
Previous Page
Page 2 of 2